# US 2024/0189246 A1 · Multifunctional Nanoparticles For Prevention And Treatment Of Atherosclerosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189246 A1
- Document ID: US20240189246A1
- Status: Published application
- Kind: A1
- Application number: 18/510,816
- Filed: 2023-11-16
- Published: 2024-06-13
- Earliest claimed: 2017-07-14
- Assignees: Drexel University
- Applicants: Drexel University
- Inventors: Yinghui Zhong; Jia Nong; Zhicheng Wang
- Web page: https://patentgrep.com/patent/US20240189246A1

## CPC

- A61K 9/5169: {Proteins, e.g. albumin, gelatin}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/5115: {Inorganic compounds}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 9/5138: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 31/12: Ketones
- A61K 31/65: Tetracyclines
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to nanoparticles for preventing, treating and reversing atherosclerosis.

## Claims

### Claim 1

Nanoparticles having a hydrodynamic diameter of from about 10 to about 400 nm, comprising a polymer comprising positively charged polymer and at least one anionic polymer comprising sulfate groups, phosphate groups, carboxyl groups, or a combination thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the at least one anionic polymer comprises sulfate groups.

### Claim 3 (depends on 2)

The method of claim 2, wherein the at least one anionic polymer is dextran sulfate, cellulose sulfate, heparin, heparin sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, alginate sulfate, aggrecan, fucoidan, or polystyrene sulfonate.

### Claim 4 (depends on 1)

The method of claim 1, wherein the at least one anionic polymer comprises phosphate groups.

### Claim 5 (depends on 4)

The method of claim 4, wherein the at least one anionic polymer comprises polyphosphate, DNA, or RNA.

### Claim 6 (depends on 1)

The method of claim 1, wherein the at least one anionic polymer comprises carboxyl groups.

### Claim 7 (depends on 6)

The method of claim 6, wherein the at least one anionic polymer is hyaluronic acid, pectin, carboxymethyl dextran, carboxymethyl amylose, carboxymethyl cellulose, carboxymethyl beta-cyclodextrin, poly(acrylic acid), or combinations thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the at least one positively charged polymer contains an amine group.

### Claim 9 (depends on 1)

The method of claim 1, wherein the at least one positively charged polymer is chitosan, glycol chitosan, gelatin type A, or PEI.

### Claim 10 (depends on 9)

The method of claim 9, wherein the chitosan has an average molecular weight (Mw) of from about 10 to about 400 kDa.

### Claim 11 (depends on 1)

The method of claim 1, wherein the at least one anionic polymer has a Mw of greater than about 1 kDa.

### Claim 12 (depends on 1)

The method of claim 1, wherein the nanoparticle further comprises an active agent that is an antibiotic, an oxygen scavenger, anti-inflammatory, low-density lipoprotein (LDL) anti-oxidant, agent that reduces uptake of oxidized LDL, agent that increases high-density lipoprotein (HDL) release, or combinations thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein the active agent is minocycline or curcumin.

### Claim 14 (depends on 1)

The method of claim 1, wherein the nanoparticle comprises:
(i) dextran sulfate, heparin, alginate sulfate, alginate, chondroitin sulfate, polyphosphate, and chitosan;
(ii) dextran sulfate, chondroitin sulfate and chitosan;
(iii) dextran sulfate, alginate, and chitosan;
(iv) chondroitin sulfate, hyaluronic acid, and heparin;
(v) heparin, chondroitin sulfate, and chitosan; or
(vi) heparin, hyaluronic acid, and chitosan.

### Claim 15 (depends on 1)

The method of claim 1, wherein the nanoparticle further comprises a metal ion.

### Claim 16 (depends on 15)

The method of claim 15, wherein the metal ion is a monovalent or divalent metal ion.

### Claim 17 (depends on 16)

The method of claim 16, wherein the monovalent ion is Nat.

### Claim 18 (depends on 16)

The method of claim 16, wherein the divalent metal ion is an alkaline earth metal.

### Claim 19 (depends on 18)

The method of claim 18, wherein the alkaline earth metal is Ca2+ or Mg2+.

### Claim 20 (depends on 1)

The method of claim 1, wherein the nanoparticles bind to the cholesterol.

### Claim 21

A method for treating atherosclerosis, preventing the progression of atherosclerosis, inhibiting oxidized LDL uptake by macrophages, reducing low density lipoprotein levels, elevating apolipoprotein-A1 (ApoA1) production by foam cells, or preventing foam cell formation in a subject, comprising administering nanoparticles to the subject, the nanoparticles having a hydrodynamic diameter of from about 10 to about 400 nm and comprising at least one positively charged polymer and at least one anionic polymer comprising sulfate groups, phosphate groups, carboxyl groups, or a combination thereof, wherein the at least one positively charged polymer, the at least one anionic polymer, or combination thereof has a hydrophobic component.
